Stocktoria
Foghorn Therapeutics Inc. FHTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-23
Foghorn Therapeutics Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M | $430,000 | — |
| R&D expense | $85.5M | $94.5M | $109.7M | $105.6M | $80.3M | $57.7M | $44.4M |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M | -$100.7M | -$68.5M | -$51.1M |
| Interest expense | — | — | — | — | $1.9M | $979,000 | $540,000 |
| Income tax | $0 | $0 | $4.2M | $0 | — | $0 | $0 |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$108.9M | -$101.3M | -$68.8M | -$51.1M |
| EPS (diluted) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 | $-6.23 | — |
| Operating cash flow | -$86.1M | -$100.4M | -$118.1M | $193.6M | -$50.2M | -$31.3M | -$46.3M |
| Free cash flow | -$86.1M | -$101.3M | -$119.3M | $192.4M | -$53.6M | -$47.5M | -$47.3M |
| Cash & equivalents | $80.9M | $55.5M | $80.3M | $52.2M | $101.1M | $92.8M | $15.0M |
| Total assets | $198.1M | $284.0M | $285.9M | $404.9M | $519.8M | $255.6M | $22.3M |
| Total liabilities | $306.6M | $329.5M | $363.1M | $404.8M | $422.9M | $109.4M | $23.8M |
| Shareholders' equity | -$108.5M | -$45.5M | -$77.2M | $112,000 | $96.9M | $146.2M | -$88.0M |
Growth · year-over-year · Revenue CAGR 135.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +36.8% | -33.8% | +77.6% | +1357.8% | +206.7% | — | — |
| Free cash flow growth | — | — | -162.0% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.